Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 24 Jun 2022 for Alaunos Therapeutics, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Christopher Bowden: trading record in brief
Christopher Bowden is a declared insider at 2 companies (senior executive); the most frequent names are Agios Pharmaceuticals, Inc. and Alaunos Therapeutics, Inc. In total, 6 filings cover trades dated from 4 March 2021 to 22 June 2022.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Most recently, on 24 June 2022, the filings show a share grant in Alaunos Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Christopher Bowden
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
40,000 shares0Common StockSEC:0000899243-22-023978:0
1,885 shares@ US$39.7612.1% of flowCommon stockSEC:0001439222-21-000059:0
2,502 shares@ US$39.7616.1% of flowCommon stockSEC:0001439222-21-000058:0
7,149 shares@ US$39.7645.0% of flowCommon stockSEC:0001439222-21-000057:0
4,268 shares@ US$39.7626.8% of flowCommon stockSEC:0001439222-21-000056:0
4,167 shares0Common StockSEC:0001209191-21-030737:0
6 of 6 declarations
